| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/23/2002 | CN1332797A Bleaching enzymes and detergent compositions comprising them |
| 01/23/2002 | CN1332640A DDS compounds and method for assaying the same |
| 01/23/2002 | CN1332639A External preparation |
| 01/23/2002 | CN1332635A Controlled release formulation comprising GnRH-II |
| 01/23/2002 | CN1332632A Preventives for hepatopathy |
| 01/23/2002 | CN1332630A Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders |
| 01/23/2002 | CN1332629A Pharmaceutical composition |
| 01/23/2002 | CN1332627A Method of producing vitamin powder |
| 01/23/2002 | CN1332626A Inhalation system |
| 01/23/2002 | CN1332625A Nanocapsules and method of production thereof |
| 01/23/2002 | CN1332622A Method and apparatus for improved administration of pharmaceutically active compounds |
| 01/23/2002 | CN1332188A Polymer gel for orally taken and colon released medicine and its prepn |
| 01/23/2002 | CN1332016A Biodegradable carrier and biodegradable transfer system |
| 01/23/2002 | CN1078250C Reshaped monoclonal antibodies against immunoglobulin isotype |
| 01/22/2002 | US6340742 Erythropoietin conjugates |
| 01/22/2002 | US6340701 Taxanes chemically linked to cell binding agent for delivering to specific cell population in targeted fashion |
| 01/22/2002 | US6340698 Pharmaceutical solution, substantially free of cyclodextrin, for oral administration comprising itraconazole or saperconazole, acid and one or more alcoholic cosolvents |
| 01/22/2002 | US6340695 Rapid onset formulation |
| 01/22/2002 | US6340672 Parasiticidal formulation and a method of making this formulation |
| 01/22/2002 | US6340671 Stable compositions for parenteral administration and their use |
| 01/22/2002 | US6340476 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 01/22/2002 | US6340475 Extending the duration of drug release within the stomach during the fed mode |
| 01/22/2002 | US6340473 Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| 01/22/2002 | US6340470 Soluble isoflavone composition and method for preparing the same |
| 01/22/2002 | US6340467 Useful as an ointment, balm or salve for wounds |
| 01/22/2002 | US6340460 Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry |
| 01/22/2002 | CA2192424C Novel paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy |
| 01/22/2002 | CA2115564C Escherichia coli o-polysaccharide-protein conjugate vaccine |
| 01/22/2002 | CA2107556C Increasing blood-brain barrier permeability with permeabilizer peptides |
| 01/22/2002 | CA2097801C Method of producing collagen particles, and the use of such particles as substrates for active substances |
| 01/22/2002 | CA2095728C A gel-forming liquid carrier composition |
| 01/22/2002 | CA2036906C Coatings for stable sustained release preparations |
| 01/19/2002 | CA2315815A1 Topical pain relief composition and carrier |
| 01/17/2002 | WO2002004616A1 RECOMBINANT α-L-IDURONIDASE, METHODS FOR PRODUCING AND PURIFYING THE SAME AND METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES THEREOF |
| 01/17/2002 | WO2002004570A2 Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| 01/17/2002 | WO2002004499A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | WO2002004487A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 01/17/2002 | WO2002004483A1 Biologically active protein conjugates formed by first protecting active site |
| 01/17/2002 | WO2002004034A2 Polymer-bound metal-containing compositions |
| 01/17/2002 | WO2002004025A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002004015A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | WO2002004012A1 Anhydrous pharmaceutical composition of vancomycin for topical use |
| 01/17/2002 | WO2002004008A2 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | WO2002004006A2 Method for improving the efficacy of artificial insemination of non-human animals |
| 01/17/2002 | WO2002003987A2 Pharmaceutical compositions of estrogenic agents |
| 01/17/2002 | WO2002003972A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002003969A2 Transdermal therapeutic system for highly dispersed silicon dioxide |
| 01/17/2002 | WO2002003965A1 Method for formulating healthcare products with enhanced stability |
| 01/17/2002 | WO2002003964A1 Oral pharmaceutical composition with controlled release and prolonged absorption |
| 01/17/2002 | WO2002003962A2 Drug delivery system for poorly water soluble drugs |
| 01/17/2002 | WO2002003961A1 Microspheres and adjuvants for dna vaccine delivery |
| 01/17/2002 | WO2002003960A1 Particulate vectors for improving oral absorption of active principles |
| 01/17/2002 | WO2002003958A1 Novel aerosol formulation containing a polar fluorinated molecule |
| 01/17/2002 | WO2002003954A2 Non swellable suppository comprising at least one biocompatible, non-biodegradable polymer and a controlled release formulation |
| 01/17/2002 | WO2002003945A1 Use of oligosaccharides to stimulate beta-endorphin production |
| 01/17/2002 | WO2002003914A2 Improved thyroid hormone formulations |
| 01/17/2002 | WO2002003896A1 Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| 01/17/2002 | WO2002003848A2 Method for opening the blood-brain barrier |
| 01/17/2002 | WO2001078693A3 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 01/17/2002 | WO2001068138A3 Intradermal-penetration agents for topical local anesthetic administration |
| 01/17/2002 | WO2001049249A3 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| 01/17/2002 | WO2001047560A3 Particulate vitamin composition |
| 01/17/2002 | WO2001044291A3 Polynucleotid encoding the rg1 polypeptide |
| 01/17/2002 | WO2001043722A3 Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| 01/17/2002 | WO2001040446A3 Pour-on formulations |
| 01/17/2002 | WO2001039815A3 Targeted drug delivery with a cd44 receptor ligand |
| 01/17/2002 | WO2001035905A3 Personal care articles comprising cationic polymer coacervate compositions |
| 01/17/2002 | WO2001030997A3 Microbe, microbial exopolysaccharide, and uses thereof |
| 01/17/2002 | WO2001030996A3 Microbial exopolysaccharide and uses thereof |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001021656A3 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001019407A3 Taxane prodrugs |
| 01/17/2002 | WO2001019406A3 Amphiphilic prodrugs |
| 01/17/2002 | WO2001019305A8 Water absorbent keratin and gel formed therefrom |
| 01/17/2002 | WO2001017565A3 Polyoxyalkylenes conjugates as enzyme inhibitors |
| 01/17/2002 | WO2001010468A3 Drug-carrier complexes and methods of use thereof |
| 01/17/2002 | US20020007028 Graft copolymer of ethylenically unsaturated nonionic monomers and terminally unsaturated acrylic acid oligomers or polymers; drug delivery |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006921 Dopaminergic agent |
| 01/17/2002 | US20020006913 Maintenance of Dna; reduce damage |
| 01/17/2002 | US20020006903 Genetic engineering |
| 01/17/2002 | US20020006900 Colon cancer KH-1 and N3 antigens |
| 01/17/2002 | US20020006898 Trimethyl lock based tetrapartate prodrugs |
| 01/17/2002 | US20020006894 Nonantigenic stabilizer and physiologically active substance |
| 01/17/2002 | US20020006893 Method of modulating cellular activity |
| 01/17/2002 | US20020006892 Serum albumin compositions for use in cleansing or dermatological products for skin or hair |
| 01/17/2002 | US20020006450 Improved physical properties and shelf life, in the form of powdered clathrates in which Aureobacidium culture solution as a guest is included in cyclodextrin as a host component |
| 01/17/2002 | US20020006446 Five medicinal plants from Thailand, comprising Houttuynia cordata, Combretum quadrangulare, Mimusops elengi, Randia siamensis, and Borassus flabellifer; maintain Kamofsky performance status greater than or equal to ninety |
| 01/17/2002 | US20020006443 Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form |
| 01/17/2002 | US20020006442 Injectable aqueous dispersions of propofol |
| 01/17/2002 | US20020006441 Pharmaceutical composition containing diphosphonic acid or salt thereof |
| 01/17/2002 | US20020006433 Chewable tablet comprising amoxycillin trihydrate in which the chewable base comprises mannitol which is at least twenty-five percent by weight of the tablet; treating bacterial infection in a pediatric patient |
| 01/17/2002 | US20020006432 Bifidobacterium in the treatment of inflammatory disease |
| 01/17/2002 | US20020006418 Composition to enhance permeation of topical skin agents |
| 01/17/2002 | US20020006417 Heating the fill mass, cooling the fill mass, and encapsulating the fill mass into the capsule immediately after cooling; nutrients or drugs such as saquinavir |
| 01/17/2002 | US20020006410 Method for treating inflammatory diseases using heat shock proteins |
| 01/17/2002 | US20020006407 Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| 01/17/2002 | US20020006400 Recombinant human CLN2 protein and methods of its production and use |
| 01/17/2002 | US20020006378 Paramagnetism, photosensitivity; imaging, diagnosis, drug delivery |